Genmab — November 2017
-
Winkel svarer altid undvigende på kritiske eller kontroversille spørgsmål. Sjældent at Q&A tilfører ny viden.
-
Solid data er som Novod skriver i dag: This is a major and underappreciated value trigger in Genmab and we continue to believe that the recent share price slump is a great buying opportunity. YTD Genmab has significantly underperformed the Nasdaq Biotech Index, which we find unwarranted.
-
Nogen der har et bud på, hvor meget de mange dara er i gang og startet op fornylig kan påvirke det nuværende salg i negativ retning?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind